In Vitro Bedaquiline and Clofazimine Susceptibility Testing in Mycobacterium abscessus

Antimicrob Agents Chemother. 2022 May 17;66(5):e0234621. doi: 10.1128/aac.02346-21. Epub 2022 Apr 14.

Abstract

Bedaquiline and clofazimine are increasingly used to treat infections with Mycobacterium abscessus. We determined distributions of MICs by broth microdilution for bedaquiline and clofazimine for 61 M. abscessus clinical isolates using different media and incubation times. We show that incubation time and growth media critically influence the MIC. Our data will aid in defining future clinical breakpoints for in vitro susceptibility testing for bedaquiline and clofazimine in M. abscessus.

Keywords: ECOFF; MIC; Mycobacterium abscessus; antibiotic susceptibility testing; bedaquiline; clofazimine; epidemiological cutoff.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Clofazimine / pharmacology
  • Clofazimine / therapeutic use
  • Diarylquinolines / pharmacology
  • Diarylquinolines / therapeutic use
  • Humans
  • Microbial Sensitivity Tests
  • Mycobacterium Infections, Nontuberculous* / drug therapy
  • Mycobacterium Infections, Nontuberculous* / microbiology
  • Mycobacterium abscessus*

Substances

  • Anti-Bacterial Agents
  • Antitubercular Agents
  • Diarylquinolines
  • bedaquiline
  • Clofazimine